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Abstract
Purpose: In prostate focal therapy, it is important to accurately localize malignant lesions in order to increase biological effect of
the tumor region while achieving a reduction in dose to noncancerous tissue. In this work, we proposed a transfer learning–based
deep learning approach, for classification of prostate lesions in multiparametric magnetic resonance imaging images. Methods:
Magnetic resonance imaging images were preprocessed to remove bias artifact and normalize the data. Two state-of-the-art deep
convolutional neural network models, InceptionV3 and VGG-16, were pretrained on ImageNet data set and retuned on the
multiparametric magnetic resonance imaging data set. As lesion appearances differ by the prostate zone that it resides in, separate
models were trained. Ensembling was performed on each prostate zone to improve area under the curve. In addition, the
predictions from lesions on each prostate zone were scaled separately to increase the area under the curve for all lesions
combined. Results: The models were tuned to produce the highest area under the curve on validation data set. When it was
applied to the unseen test data set, the transferred InceptionV3 model achieved an area under the curve of 0.81 and the
transferred VGG-16 model achieved an area under the curve of 0.83. This was the third best score among the 72 methods from
33 participating groups in ProstateX competition. Conclusion: The transfer learning approach is a promising method for
prostate cancer detection on multiparametric magnetic resonance imaging images. Features learned from ImageNet data set can
be useful for medical images.
Keywords
mpMRI, prostate lesion, transfer learning, AI, convolutional neural network, focal therapy
Abbreviations
ADC, apparent diffusion coefficient; AS, anterior fibromuscular stroma; AUC, area under the curve; CAD, computer-aided
detection; DCE-MRI, dynamic contrast-enhanced MRI; DCNN, deep convolutional neural networks; DWI, diffusion-weighted
imaging; FPR, false-positive ratio; mpMRI, multiparametric magnetic resonance imaging; PI-RADS, Prostate Imaging Reporting and
Data System; POI, points of interest; PSA, prostate-specific antigen; PZ, peripheral zone; ROC, receiver operating characteristics;
SV, seminal vesicle; T2W, T2-weighted imaging; TPR, true-positive ratio; TZ, transitional zone.
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Introduction

1

Prostate cancer is common and a frequent cause of cancer
death. In 2017, there are estimated to be 161 000 new prostate
cancer diagnoses and approximately 26 700 prostate cancer
deaths1 in the United States. It is also the most commonly
diagnosed cancer in men and the seventh leading cause of male
cancer death worldwide.2 The current practice for prostate cancer detection involves using prostate-specific antigen (PSA)
testing for screening,3 followed by transrectal needle biopsy
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for PSA positive patients. However, this practice has been
questioned recently because of the poor efficacy.4-6 One problem is that PSA can elevate in a number of benign conditions
such as benign prostatic hyperplasia and prostatitis. Studies
have found that less than 1 in 3 men with an elevated PSA
would have prostate cancer detected in biopsy.7-9 Another issue
is that due to the lack of image guidance, the needle biopsy
could miss the malignant lesion, causing understaging or even
false negatives.10
Recently, multiparametric magnetic resonance imaging
(mpMRI) has been found to be a valuable diagnostic tool for
the detection, localization, and staging of prostate cancer.11
The mpMRI includes T2-weighted imaging (T2W) sequence,
diffusion-weighted imaging (DWI), and dynamic contrastenhanced MRI (DCE-MRI). The combination of morphological and functional information provided by mpMRI allows for
precise identification of prostatic lesions while avoiding the
sampling error of biopsies. Studies have shown that the mpMRI
is able to detect intermediate/high-grade prostate cancer as
reliable as systematic biopsies,12-14 thus reducing the number
of biopsy samples and improving the accuracy of the diagnosis.
The challenge with adopting mpMRI for prostate cancer
diagnosis and staging is how to interpret the data in a reliable
and replicable fashion. Radiological societies from Europe and
North America have established Prostate Imaging Reporting
and Data System (PI-RADS) guideline and subsequently PIRADSv2 to address this problem.15,16 It has been shown that
the PI-RADSv2 can achieve good performance.17-19 Unfortunately, studies also show that there exist significant interobserver variabilities from radiologists based on experience and
training.17-19 In addition, as radiologists have to review multiple three-dimensional image sets, visual and mental fatigue
could be a factor that can affect the accuracy of the
interpretation.20
Computer-aided detection (CAD) system holds great potential in assisting radiologists. It can provide more reproducible
results while consuming less time. More importantly, it is not
restricted by the limitation of human’s visual system. Using
data characterization algorithms, large amount of quantitative
features, termed as radiomic features, can be extracted from
images. Relationships can be established between those radiomic features and diagnosis through machine-learning algorithms. Several studies have reported the encouraging result
for prostate lesion classification.21-23
Since the success of AlexNet in ImageNet competition24 in
2012, deep convolutional neural networks (DCNN) has dramatically improved the performance of computer algorithms in
many tasks.25 In medical imaging domain alone, there are
already many examples of DCNN based algorithms exceeded
human experts’ performance, including diabetic retinopathy
diagnosis,26 skin cancer diagnosis,27 and breast cancer metastases from pathology images.28
From November 2016 to January 2017, Society of PhotoOptical Instrumentation Engineers, along with the support of
American Association of Physicists in Medicine and National
Cancer Institute held the prostateX grand challenge to identify
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top-performing quantitative image analysis methods for the
diagnostic classification of clinically significant prostate
lesions from mpMRI images.29 In this article, we present our
DCNN approaches to this problem. We experimented with
transfer learning from 2 state-of-art DCNN models trained on
ImageNet data set. Proper data preprocessing as well as ensembling were applied. An innovative rescaling scheme was created for mixing scores predicted for lesions at different prostate
zone. One of our models achieved the third best score among
72 methods from 33 participating groups in this open
competition.

Materials and Methods
Deep Convolutional Neural Network
Artificial neural network is made up with network of neurons
that has learnable weights and biases. It has been proved mathematically that a feed-forward network with as few as one
single hidden layer of finite neurons can approximate (learn)
any continuous function.30 As more layers are stacked, the
network can have better learning capacities. Deep convolutional neural network, which uses many convolutional and
pooling layers, has demonstrated excellence performance in
image classification. Different neural network architectures
have been proposed to improve the classification performance
in ImageNet. VGG-Net31 adopts a simple design with only 3 
3 convolution and 2  2 pooling layers, but the deep network
constructed produced better accuracy (92.7%) than previous
models in 2014 ImageNet competition. 32 The same year,
InceptionNet,33,34 a deeper network design with the innovative
inception modules, achieved the top accuracy of 93.4%.32 For
this study, we adopted both designs that were proved to be
successful. In the subsequent text, model 1 refers to VGG and
model 2 refers to InceptionNet.

Data Set
The data set provided by prostateX organizer was collected
from a single institution with one of the 2 Siemens (Munich,
Germany) 3T MR scanners, the MAGNETOM Trio and
Skyra.23 For each patient, T2W, DWI, and DCE imaging were
performed. The T2W was performed in Transverse (T2W_T),
Coronal (T2W_C), and Sagittal (T2W_S) planes. For the DWI
scans, the scan at b ¼ 800 s/mm2 (Bval800) as well as the
apparent diffusion coefficient (ADC) map were provided. For
DCE scans, the volume transfer constant (K-trans) images were
computed.
Each study was read by expert radiologists. The suspected
areas were marked and biopsy was performed to provide
ground truth. Additional negative samples were provided by
randomly sampling the patient that was confirmed to be
disease-free. Based on human experience, the particular features of prostate lesion differ based on prostate zone.15,18 Coordinates of these points of interest (POI) and the prostate zonal
information were provided.
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Table 1. Distribution of POI by Zone (# of Malignant/Total).a
Data Set
Training
Validation
Test

PZ

TZ

AS

SV

36/191
10/58
?/113

9/82
1/19
?/59

31/55
7/12
?/34

0/2
0/0
?/2

Abbreviations: AS, anterior fibromuscular stroma; POI, points of interest; PZ,
peripheral zone; SV, seminal vesicle; TZ, transitional zone.
a
The ground truth for test data set was not disclosed (labeled by question
mark).

During the training phase of the competition, data set containing 330 POIs from 204 patients was released. The ground
truth for those training data was also provided. During the test
phase of the competition, data set containing 208 POIs was
provided. The POIs distribute unevenly into 4 different prostate
zones: peripheral zone (PZ), transitional zone (TZ), anterior
fibromuscular stroma (AS), and seminal vesicle (SV) as shown
in Table 1. Since there are no malignant SV lesions in training
data, the model cannot learn image features that define a malignant SV lesion. Therefore, our model will classify all SV
lesions as benign.
When evaluating machine-learning models, the validation
step helps to identify the best parameters for the model while
also prevent it from becoming over-fitted. Two of the most
popular strategies to perform the validation step are the holdout
strategy and the K-fold strategy.35,36 The holdout validation
sets aside a chunk of training data to evaluate the model performance. The K-fold strategy divides the training set into K
folds (or chunks) and then trains the model K times, each time
leaves a different fold out of the training data as a validation
set. We tried with both validation strategies. For model 1, we
used holdout validation. Approximately one-third (patient id
00-64) of the data were set aside as validation data. The distribution of lesion across zones resembles the distribution in training data set as shown in Table 1. For model 2, we use 3-fold
cross-validation technique. Training data set was randomly
grouped into 3-folds for each prostate zone. The ratio of malignant versus benign was kept the same across the folds.
As shown in Table 1, training data set consists of mostly
negative findings. Especially in transition zone, 89% of the
lesions provided are negative. Such highly unbalanced data set
can easily bias DCNN to predict negative for almost all cases.
To combat this issue, we oversample the positive cases by
increasing the data augmentation while undersample the negative cases by reducing the data augmentation during the model
training process.

Preprocessing
One of the major drawbacks of MRI has been the lack of
quantifiable interpretation of image intensities. Within the
same image, the intensities for the same material vary as they
are affected by bias field distortions. In addition, not only do
MR images taken on different scanner vary in image intensities, but the images for the same patient on the same scanner at

different times may appear differently from each other due to a
variety of scanner-dependent variations.37,38 Therefore, it is
important to normalize the MR intensity first. For the T2W
MRI, Bias correction with ITK39 function N4ITKBiasFieldCorrection40 and histogram matching with ITK39 function HistogramMatchingImageFilter38 were performed to normalize
the data. The N4ITKBiasFieldCorrection removes the intensity
variation of homogeneous tissue region for each image individually. The HistogramMatchingImageFilter ensures that the
intensity distribution is consistent across the patients.
Lesions were located with the provided world coordinate in
each mpMRI. A 1.6 cm  1.6 cm Region-Of-Interest box with
grid size of 0.5 mm was used to crop the lesion from the T2
MRI slice. The same grid was used to sample the ADC, B-value
and K-trans volume using the world coordinates, resulting in
corresponding 32  32 matrixes as well. This process is
repeated for T2 Transversal, Coronal and Sagittal scans,
obtaining 3 orthogonal slices centered at POI. Images from
different MRI scans are combined into RGB channels for the
deep learning algorithm to process. Figure 1 illustrates an
example of combining T2W_T scan, ADC map, and DCE Ktrans image into an image (labeled as TAD). Other combinations including T2W_S-ADC-DCE (SAD), T2W_C-ADCDCE (CAD), T2W_T-Bval-DCE (TBD), T2W_S-Bval-DCE
(SBD), and T2W_C-Bval-DCE (CBD) were similarly created.
Data augmentation was performed with random rotation and
translation. Since the clinical classification of prostate lesion
depends on the size and contrast of the lesion, other augmentation techniques popular in natural scene classification, such as
intensity shift, scaling, color jittering, was not used.

Transfer Learning
As networks get deeper for better learning capacity, the number
of parameters in the model (model size) also grows. This not
only increases the computation complexity but also requires
more training data. ImageNet contains 14 million pictures, with
at least 500 unique images for each object. For diabetic retinopathy diagnosis,26 128 000 images are available. However, for
this study, only 330 lesions are provided as training data. We
were concerned that this amount of data is not enough to train a
full-fledged DCNN from scratch. Fortunately, a technique called
transfer learning where a DCNN trained on one problem is
applied to a different but related problem can alleviate the
demand for big training data set. Many studies have demonstrated the effectiveness of this approach.41-43 Therefore, we
adopted the transfer learning approach. We started from the
ImageNet pretrained InceptionV3 model (model 1) and VGG16 model (model 2), and modified the last fully connected layer
to produce 2 classes (benign and malignant). For model training,
only the weights on the last layer were allowed to change.
The model’s hyper parameters were tuned based on the performance on validation data set to avoid overfitting. Default
learning rates for training a modern DCNN from scratch are
typically higher than necessary for our transfer learning models
which only train the final classification stage. Based on
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Figure 1. Combing multiparametric magnetic resonance imaging (mpMRI) images into RGB channels and augmentation with random rotation
and translation.

validation data performance, we determined an initial learning
rate of 1e-5 with 10-fold reduction for every 100 epochs training.
Dropout was applied to fully connected layers with probability
of .5. Cross-entropy loss was used and was minimized using
stochastic gradient descent with Nesterov momentum of 0.9.

Postprocessing
A popular postprocessing technique in machine learning to
increase the accuracy of the prediction is ensembling. The
ensembling refers to the technique of combining predictions
of different models. It reduces both bias and variance of the
final results, thus reduces the risk of overfitting and increasing the final score. There are many ensembling techniques,
such as bagging, boosting, blending, and stacking. Due to
the time constraint of the competition, we implemented a
very simple ensembling approach. For each model, we averaged the scores of 50 augmented images (fixed translation
and rotation) of the same lesion as the model output. For
each prostate zone, we picked the 2 best performing models
based on the validation data set. Then for each lesion in the
test data set, we averaged the prediction from the 2 best
performing models.
The ProstateX challenge uses the area under the receiver
operating characteristics (ROC) curve (AUC) as the metric for
final ranking. The ROC curve is defined as a plot of truepositive ratio (TPR) against false-positive ratio (FPR) when
the threshold c moves on a real number line. Our DCNN models will analyze each lesion image and produce a confidence
score of being malignant between 0 and 1. Varying the threshold c will produce different TPR and FPR and form an ROC
curve:
ROCðx; yÞ : x ¼ FPRðcÞ; y ¼ TPRðcÞ j c 2 ½0; 1

ð1Þ

Figure 2. Illustration of maximizing the area under the curve (AUC)
when lesions from 2 different zones are combined. Red circles illustrate positive cases and blue cross illustrate negative cases. The AUC
will be less than 1.0 if we simply combine cases from 2 zones.
However, if we rescale the scores for zone 2 by 0.67 before mixing the
cases, the AUC of 1.0 can be achieved.

In our study, lesions from different prostate zones were
trained and evaluated separately. It had been observed that the
scores from different prostate zone carry different confidence,
likely that due to the different appearance of the lesion and the
different amount of training images available at each prostate
zone. In that case, simply combining the scores from different
prostate zone may not be the optimal solution. Figure 2 is a
simple illustration of the problem. Scores predicted for zone 1
and zone 2 are plotted. Predictions for zone 1 lesions achieved a
perfect AUC of 1.0, where the threshold of 0.4 can separate the
positive and negative cases. On the other hand, the predictions
for zone 2 lesions also achieved a perfect AUC of 1.0 but with
optimal threshold at 0.6. When the scores for all lesion zones
were combined, there is no threshold value that can perfectly
separate the positive and negative cases and the AUC will be
less than 1.0. However, if we rescale the scores for zone 2 by
0.67 before combining the scores, the AUC of 1.0 can be
achieved for all lesions.
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Figure 3. Effect of bias field correction of MRI image. (A) Original image (B) bias-field corrected. The intensity variation in (A) is greatly
reduced in (B).

Figure 4. Example of improvement of area under the curve (AUC) from ensembling. A, Receiver operating characteristics (ROC) for anterior
fibromuscular stroma (AS) lesions in validation data set without ensembling. B, ROC for same lesions with ensembling. The AUC increased
from 0.80 to 0.88.

Based on validation ROC curves at each prostate zone, we
designed simple heuristic strategy to remap the raw scores to
improve the combined AUC. We first identify the threshold
value coi for zone i that satisfies FPRi ðcoi Þ ¼ 1  TPRi ðcoi Þ.
Then for predicted score (si) at zone i, we create this mapping
0
to create a new score (Si ):
8
>
>
<

si
 0:5 ðsi  coi Þ
coi
}
Si ¼
:
1  si
>

0:5
ðs
>
co
Þ
1

>
i
i
:
1  coi

ð2Þ

Note that this transformation only uses one control point. It
is possible to design a piecewise mapping of the predicted score
that can achieve a higher combined AUC than this simple
formula. However, due to the limited validation data, the shape
of the validation AUC for each prostate zone can be different
from the test data. A complex score mapping may over-fit the
validation data. Therefore, for this competition, we did not
attempt to craft other complex score mappings.

Experiment and Results
Figure 3 demonstrates the correction of image intensity variation by bias field distortion by the N4ITKBiasFieldCorrection

function. The most obvious change is in the subcutaneous fat. It
exhibits a much brighter appearance at the edges in the original
image (Figure 3A). This nonuniformailty has been corrected in
Figure 3B. In addition, the apparent contrast between the left
and right prostate PZ in the original image seems to be the
result of the bias field distortion, as the contrast reduced significantly in Figure 3B.
Figure 4 demonstrated the improvement of AUC from
ensembling. A single model achieved an AUC of 0.80 for AS
lesions in the validation data set. After averaging predicted
scores from 50 augmented images of each lesion, and over
predictions from different models, we achieved a dramatic
improvement to an AUC of 0.88.
Figure 5 demonstrated the improvement of AUC by considering the difference in score scale across the zones. Only
2 zones were shown for simplicity. For lesions in PZ zone
and AS zone, the model achieves AUC of 0.82 and 0.91,
respectively (Figure 5A-B). If we simply combine the scores
from 2 zones, we got ROC curve shown in Figure 5C with
AUC of 0.82. However, if we transform the scores following equation 2 before combining, an AUC of 0.86 can be
obtained (Figure 5D).
With the model tuning and postprocessing, we were able to
achieve an AUC of 0.90 on the validation data set for all lesions
combined for model 1 and an AUC of 0.86 for model 2.
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Figure 5. Rescale score from different zone to maximize area under the curve (AUC). A, Receiver operating characteristics (ROC) for
peripheral zone (PZ) lesions in validation dataset. B, ROC for anterior fibromuscular stroma (AS) lesions in validation dataset. C, ROC of a
simple combine. The AUC is 0.82. D, ROC of scaling AS score before combining with PZ. The AUC is 0.86.

by our models on the test set. Model 2 (solid line) produces
slightly better AUC value (0.83) than model 1 (0.81). The AUC
of 0.83 is the third best score of the competition, behind 0.87
and 0.84 achieved by top 2 teams.

Discussion

Figure 6. Receiver operating characteristics (ROC) curve for the test
data set achieved by our models.

After the hyperparameter for the DCNN model, as well as
the postprocessing step was finalized with the validation data
set, the model was retrained with the validation data set
included as training data. The trained model was applied to the
test data set, with the same ensembling and score transformation. The final prediction scores on the test data set were submitted to organizers. Figure 6 shows the ROC curve achieved

The mpMRI images are quite different in appearance from the
photos of various natural objects in the ImageNet data set.
Therefore, it came as a pleasant surprise that our transfer learning from ImageNet models performed very well for the medical
mpMRI images. Based on the information provided by organizer, it also outperforms all those submissions that used radiomics.44 Our understanding is that the bottom layers of the
DCNN act as a feature extractor while the top layers of the
DCNN act as a classifier. The reason that DCNN-based
approach generally outperforms radiomics approach is that the
radiomics uses hand-crafted features which is limited, whereas
DCNN can generate features that are most appropriate to the
problem. The only drawback of the DCNN approach is that
when the training data set is very limited, the features learned
from training data may not be better than handcrafted features
selected by human after seen a lot more training cases from
many years of practice. As the ImageNet pretrained models
outperformed human in the classification task, we believe that
these models had extracted a greater variety of image features
than human vision. By freezing the bottom layers, we avoided
the problem of feature construction with very limited data and
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focus directly on the classifier. The good performance on our
approach seems to indicate that although the medical images
have different visual appearance as everyday objects in ImageNet, the image features (eg, contrast, size) that radiologists
rely on to read medical images are also used in the everyday
objects recognition. Note that while we believed that the provided data are not enough to train a CNN from scratch, the top 2
scorers all trained their network from scratch without employing the transfer-learning approach.29,45,46 It is possible that by
transfer learning from ImageNet, we did not pick some subtle
details that only exist in MRI images. However, the small
difference in score indicated that it does not cause a major
issue. There are many other studies that do demonstrate advantage of transfer learning over training from scratch
approaches.41,42,47,48 Therefore, it may also be that the small
differences with the top performers were due to our training
and were not fully tuned rather than the use of transfer-learning
approach. We believe that the transfer-learning technique can
be applied to other classification problems related to medical
images.
It has been reported that radiologist following PI-RADS can
achieve an AUC of 0.81 to 0.84 on detecting malignant prostate
cancer.19,49,50 It seems that our DCNN model achieves similar
performance despite seeing only 330 cases with only 76 malignant cases. While the radiologist-like performance is already
satisfactory, we believe that there is more room to improve.
Although we were provided 330 cases for training, there were
only 76 malignant examples. Due to the malignant lesion having different appearance in different prostate zones, we have to
group the lesions by prostate zones and train them separately.
Therefore, the training data for individual prostate zones were
further reduced. For TZ lesions, only 9 malignant lesions were
provided for training. As a result, only 1 to 3 malignant lesions
were in the validation data set. It is very likely that this limited
training data set did not adequately represent the variety of
lesion in the test data set, resulting decreased model performance. In addition, since the model was tuned on the validation
data set performance, the final model may over-fit the validation data set. Using K-fold validation strategy can mitigate this
issue partially. This could be one of the factors why our model
2 produced better result. We believe that with more training
data, the performance of the DCNN models can be further
improved. However, it remains to be seen what kind of performance is achievable if we have enough training data that covers
the variety of lesion appearance seen in clinical practice.
Machine learning and especially deep learning is highly
susceptible to the problem of overfitting. For improperly
designed studies, a common pitfall is to select the methods that
demonstrated the best performance on the test data set. This
process would actually over-fit the test data set. For our study,
the challenge organizer did not release the ground truth for the
test data set. While this arrangement prevented us from performing further analysis of the results as well as in-depth comparison between models, it also ensured that the AUC score
achieved was trustworthy. However, as the data came from a
single institution in the current study, it is expected that the
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trained model may produce worse results on data from other
institutions. While we implemented preprocessing steps to normalize data, these steps may not be sufficient to fully account
for the variety of MRI images in different clinical settings.
Further works are needed to study the performance degradation
on the data from a different institution and strategies to mitigate
this issue.

Conclusion
In this study, we implemented a DCNN method for prostate
lesion classification on mpMRI images. Specifically, we used a
transfer-learning approach where ImageNet pretrained DCNN
models were retuned on the mpMRI lesion image patches. Our
approach achieved the third best score in the prostateX competition. This result suggests that the transfer-learning from
ImageNet pretrained DCNN model has strong potential in
working with mpMRI images and likely other medical image
modalities as well.
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